Skip to main content
. 2023 Jun 21;15(6):e40742. doi: 10.7759/cureus.40742

Table 3. Summary of clinical outcomes of various OVs in different neoplastic disorders.

mOS: median overall survival, ORR: objective response rate, CR: complete response, OR: objective response , DIPG: diffuse intrinsic pontine glioma, pCR: pathological complete response, PR: partial response, SD: stable disease, GBM: glioblastoma multiforma, MG: malignant glioma, AA: anaplastic astrocytoma, RE: recurrent ependymoma, AEs: adverse events, PFS: progression free survival, HNSCC: hand and neck squamous cell carcinoma, NSCLC: non-small cell lung carcinoma, MPM: malignant pleural mesothelioma, CRC: colorectal cancer, LAPC: local advanced pancreatic cancer, HCC: hepatocellular carcinoma, mBC: metastatic breast cancer, PROC: platinum resistant ovarian cancer, CRPC: castrate-resistent prostatic cancer, RCC: renal cell carcinoma, CBCL: cutaneous B cell lymphoma, CLL: chronic lymphocytic leukemia.

Cancer Virus Participants Clinical outcomes Reference
  Melanoma T-VEC 436 Improved longer-term efficacy and overall survival (mOS 23.3 months, ORR 31.5%, and CR 16.9%) [45]
PVSRIPO 12 OR: 33%, pCR in two patients, no progression in 50% in 18 months [47]
Poxvirus 1 Clinical regression of the lesion with grade ½ AEs [106]
Pediatric DIPG DNX-2401 12 mOS 17,8 months, Reduction in tumor size in 75%, PR: 25%, SD: 67%, 2 patients achieved 3 years-survival. [49]
GBM G47∆ 19 mOS: 20.2 months, 1-year survival in 84.2%, PR: 1 patient, SD: 18 patients, [52]
Reolysin 15 mOS: 13.1 months,  2-year survival in 33%. [54]
Pediatric MG, AA, and RE AdV-tk 8 2-year survival: 37.5%, 2 patients > 36 months, AEs: Grade 1/2 [55]
HNSCC GL-ONC1 19 PFS in 1st year: 74.7% and in 2nd year: 64.1% OS in 1st year: 84.6%, 2nd year: 69.2% [57]
T-VEC 36 ORR: 16.7%, six paitents had PR and 8 patients had SD. [58, 59]
rAd-p53 102 Improved OS and disease-free survival rates [60]
NSCLC TG4010 222 Improved PF survival among TG4010 compared to placebo, only 4% had grade 3/4 AEs . [62]
MEM-288 11 No DLTs. SD: 2 patients and PD: 5 patients.  [107]
MPM HSV1716 12 SD: 50% [65]
Esophageal cancer OBP-301 13 ORR: 91.7%, CR: 61.5%, PR: 13% [66]
CRC Reolysin 30 PR: 20%, SD: 73.3%, mOS: 25.1 months [67]  
OH2 54 (35 with CRC) SD: 13 patients, PR: 2 patients, Tumor with lymph node metastasis regression in 2 patients [69]
LAPC HF10 9 PR: 33%, SD: 44%, mOS: 15.1 months [71]
Ad5-DS 9 SD: eight patients, PR: one patient, median PFS: 11.4 months. [73]
Reolysin 10 Disease control in 3 patients: 1 PR for 17.4 months, 2 SD for 9 and 4 months. Grade 1-2 AEs. [108]
HCC AdV-tk 77 Improved 5-year survival [76]
JX-594 30 Improved OS with CR in one patient  
mBC AdV-tk 28 Clinical benefit: 21.43%, PR: 1 patient, SD: 3 patients, CR: 2 patients (1 patient remains disease-free for 39 months). [79]  
T-VEC 9 pCR: 55% with lymph node metastasis regression in 3 patients, [80]  
Reolysin 74 Improved mOS: 17.4 months [109]
    PROC Olvi-Vec   12 SD: 64%, Improved OS in 3 patients > 30 months, [83]  
enadenotucirev 38 SD: 35%, reduction in tumor burden in 65% [84]  
    CRPC GEN0101 9 SD: 67% and reduction of lymph node metastasis in 3 patients  [90]  
AdV PSA/MUC1/brachyury 18 SD: 5 patients, PR: 1 patient, Notable decline in PSA levels.  [91]
  Bladder cancer CG0070 35 CR in 6, 12, and 18 months: 44%, 30%, and 23% respectively [94, 95]
Nadofaragene firadenovec   157 Improved 2-year survival rate [97]  
RCC Pexa-Vec 16 Tumor reduction and overall disease control 75% [98]
CBCL TG1042 11 CR: 63.6% and PR: 36.4% [103]
CLL Ad-ISF35 15 PR: 20%, SD: 46.7%, with reduction in lymphadenopathy and splenomegaly [105]